THE-OPEN-GROUP
24.3.2021 10:02:14 CET | Business Wire | Press release
The Open Group , the vendor-neutral technology consortium, today announced the OSDU Data Platform Mercury Release. Developed by The Open Group OSDU™ Forum , the OSDU Data Platform is an Open Source, standards-based and technology-agnostic data platform for the energy industry that stimulates innovation, industrializes data management, and reduces time to market for new solutions.
The OSDU Data Platform will provide over time access to a vast portfolio of open and proven vendor-developed applications from a broad range of energy sources. By accessing this ecosystem, developers no longer have to develop and maintain the monolithic architecture needed to deliver unique value-add services. Now, with a single set of well-defined and industry-specific APIs, organizations can easily accelerate platform design and develop proprietary applications on top of the OSDU Data Platform.
With an Open Source approach, any company – from established corporations to start-up challenger companies – can contribute new features to the platform, supporting a variety of business workflows. All work is validated by the OSDU Program Management Committee (PMC) to ensure it is aligned with the overall direction of the Forum.
With a single view of industry data, the OSDU Data Platform can be harnessed for innovative business applications. The Mercury Release of the OSDU Data Platform is now available to Operators and Software Developers who want to:
- Liberate data from traditional silos and make all data discoverable and usable in a single data platform
- Enable new integrated exploration and development workflows that reduce overall cycle time
- Take advantage of emerging digital solutions to provide scalability and accelerate decision making
Steve Nunn, President and CEO of The Open Group, commented: “The OSDU Data Platform Mercury Release represents an important achievement by the OSDU Forum in a very short space of time. Established in 2018, the OSDU Forum has accumulated over 185 Member organizations who are collaborating together to accelerate innovation and reduce costs in the energy sector. With a standard data platform, energy companies will be able to drive innovation by integrating digital technologies and utilizing open standards for better decision making. Looking ahead, this will be imperative to meet the world’s increasing energy demands while reducing greenhouse gas emissions.”
Johan Krebbers, GM Emerging Digital Technologies / VP IT Innovation, Shell, commented: “At the heart of most energy companies’ strategies is embracing the transformational technologies taking us forward in today’s digital era. This makes the need for a common architectural design clear, one that underpins how our industry works with its data.”
David Eyton, EVP Innovation & Engineering, bp, commented: “Data is at the heart of bp’s transformation into an integrated energy company. We believe that the future of the energy industry will be data driven and dependent on its ability to manage data in a manner that promotes data sharing with partners, innovation through data science, and rapid decision making throughout the lifecycle of the energy value chains. Being a founding member of the OSDU Forum, bp has had an opportunity to be part of an organization that is fundamentally changing the data landscape for our industry. By integrating energy organizations, cloud services providers, and software vendors, the OSDU Forum is providing an opportunity for collaboration that will be beneficial for all involved. We are very excited about the Mercury Release of the OSDU Data Platform and look forward to expanding this approach into engineering, emissions, and new energy.”
To learn more about how to develop applications the OSDU Data Platform, visit the application developer community page here .
The current OSDU Forum Member List is available here .
-ENDS-
About The Open Group OSDU Forum
The Open Group OSDUTM Forum enables the Energy industry to develop transformational technology to support the world’s changing Energy needs. The OSDU Forum is available to all energy stakeholders including application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found here .
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 800 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. For more information, visit www.opengroup.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom